Eisai & BioArctic
3 shared events · Importance 4 · Last updated May 15, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Eisai holds the license to clinically develop and commercialize BioArctic's Alzheimer's drug Leqembi globally, paying royalties on sales.
Business
Eisai: Eisai, BioArctic's partner, announced a projected revenue of JPY 143.5 billion for Lecanemab in FY 2026, demonstrating strong sales growth and continued commercialization efforts for the Alzheimer's drug.
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
Regulatory
Eisai: Eisai is responsible for the clinical development, marketing authorization applications, and commercialization of Lecanemab. The FDA's extension of the PDUFA date for Lecanemab Iqlik's sBLA directly impacts Eisai's timeline for market expansion.
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab. The extension of the PDUFA date for Lecanemab Iqlik's sBLA could delay potential revenue streams for BioArctic.
May 08, 2026 · 13 articles
Business
Eisai: Eisai is mentioned as a partner with BioArctic in the development of Leqembi.
BioArctic: BioArctic is publishing its first quarter report for January - March 2026 and inviting investors, analysts, and media to a webcast and teleconference to present and comment on the report.
May 13, 2026 · 7 articles
NEWSDESK
Explore this relationship live
Track how Eisai and BioArctic interact across events, view sentiment trends, and discover connected entities.
Open Dashboard